Drug Company Hid Research Showing Arthritis Drug reduced Alzheimer s

One of the world's biggest drug firms deliberately buried data showing one of its arthritis medications could slash the risk of Alzheimer's.<br><br>Pfizer kept its finding under wraps for more than three years because, it claims, it didn't believe the evidence was strong enough.<br><br>It found the link between [https://www.google.com/search?hl=en&gl=us&tbm=nws&q=Alzheimer%27s&btnI=lucky Alzheimer's] and the drug Enbrel when analysing medical insurance claims in hundreds of thousands of people in the US.<br><br>People taking Enbrel, an anti-inflammatory used to treat rheumatoid arthritis, [http://www.recruitingblogs.com/main/search/search?q=appeared appeared] to be 64 per cent less likely to develop the memory-robbing disorder.<br><br>But after years of discussion, the company decided not to reveal what it had found, according to a document seen by the Washington Post.<br><br>Experts are sceptical of the firm's reasons not to share its 'strong' data at a time when scientists are deep into a quest to find an Alzheimer's treatment.<br><br>One suggested money - and a desire to not let others capitalise - may have been behind the decision because Enbrel's patent had almost run out.<br><br>Pfizer told MailOnline this allegation is untrue and its decision not to publish was based 'first and foremost on scientific rationale'.<br><br>Internal documents from one of the world's largest pharmaceutical companies, Pfizer, showed it found its rheumatoid arthritis medication,  [http://pharm-usa-official.com generic online] Enbrel (pictured) may be able to reduce someone's risk of developing Alzheimer's disease by as much as two thirds<br><br>Researchers working inside the $235billion (£184bn) company reportedly urged bosses to start a clinical trial to delve deeper into what they found in 2015.<br><br>This could have involved between 3,000 and 4,000 people, taken four years and cost the firm $80million (£63m), it estimated.<br><br>After internal discussions, the New York-based company decided in 2018 not to go ahead with a trial, and not to tell the research community what it had found.<br><br>RELATED ARTICLES<br>Previous<br><br>1<br>Next<br><br>Mother is awarded £18,000 after suffering a decade of 'poor'... Amazon is criticised for showing documentaries promoting... Self-harm rates have TREBLED across England since 2000 with... Cancer sufferer, 26, having a testicle removed had a... <br>Share this article<br>Share 6.3k shares A PowerPoint presentation from a Pfizer meeting the same year, seen by the Post, read: 'Enbrel could potentially safely prevent, treat and slow progression of Alzheimer's disease.'<br><br>Defending its decision not to investigate the link further, Pfizer - the maker of Viagra - said it believed the chances of success for a clinical trial were low.<br><br>And it added the findings from its insurance claims analysis, which included hundreds of thousands of people, did not meet 'rigorous' scientific standards.<br><br>'I find Pfizer's decision really difficult to understand,' Professor Rob Howard, an old-age psychiatry expert at University College London, told MailOnline.<br><br>Pfizer, headquartered in New York (pictured), told the Washington Post it did not believe its findings were scientifically robust enough to publish